Home » Stocks » Arcus Biosciences

Arcus Biosciences, Inc. (RCUS)

Stock Price: $24.05 USD 0.67 (2.87%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.37B
Revenue (ttm) 15.00M
Net Income (ttm) -94.79M
Shares Out 46.05M
EPS (ttm) -2.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $24.05
Previous Close $23.38
Change ($) 0.67
Change (%) 2.87%
Day's Open 23.61
Day's Range 22.52 - 24.14
Day's Volume 775,137
52-Week Range 6.30 - 37.41

More Stats

Market Cap 1.37B
Enterprise Value 1.21B
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.05M
Float 29.79M
EPS (basic) -2.15
EPS (diluted) -2.15
FCF / Share -2.02
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.67M
Short Ratio 1.72
Short % of Float 5.11%
Beta 1.30
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 91.46
PB Ratio 9.00
Revenue 15.00M
Operating Income -98.34M
Net Income -94.79M
Free Cash Flow -89.41M
Net Cash 158.07M
Net Cash / Share 2.77
Gross Margin -423.21%
Operating Margin -655.57%
Profit Margin -632.00%
FCF Margin -596.04%
ROA -28.28%
ROE -52.34%
ROIC -81.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(58.00% upside)
Current: 24.05
Target: 38.00
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth79.58%491.15%--
Gross Profit15.008.351.41-
Operating Income-88.71-54.86-53.44-18.18
Net Income-84.71-49.59-53.08-17.97
Shares Outstanding43.8334.621.830.86
Earnings Per Share-1.93-1.43-29.03-20.80
Operating Cash Flow-73.46-43.00-25.06-12.94
Capital Expenditures-1.93-3.74-5.51-4.10
Free Cash Flow-75.39-46.74-30.57-17.04
Cash & Equivalents18825717699.10
Net Cash / Debt18825717699.10
Book Value164235-72.33-19.99
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Arcus Biosciences, Inc.
Country United States
Employees 139
CEO Terry J. Rosen

Stock Information

Ticker Symbol RCUS
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSE: RCUS
IPO Date March 15, 2018


Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc.; and co-development and co-commercialization partnership with Gilead Sciences, Inc. for the development of cancer immunotherapies. The company was founded in 2015 and is based in Hayward, California.